Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3846060 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2KMT2ANPC1CASP3RAB9A | |
| SCHEMBL3853475 | 0.86 | SMN1; SMN2 (0.54) | SMN1; SMN2KMT2ANPC1RAB9AMAPT | |
| SCHEMBL3846821 | 0.86 | SMN1; SMN2 (0.58) | SMN1; SMN2KMT2ANPC1CASP3RAB9A | |
| SCHEMBL3846820 | 0.86 | SMN1; SMN2 (0.58) | SMN1; SMN2KMT2ANPC1CASP3RAB9A | |
| SCHEMBL3853477 | 0.86 | SMN1; SMN2 (0.54) | SMN1; SMN2KMT2ANPC1RAB9AMAPT | |
| SCHEMBL3847811 | 0.85 | SMN1; SMN2 (0.52) | SMN1; SMN2KMT2ANPC1CASP3RAB9A | |
| SCHEMBL3847809 | 0.85 | SMN1; SMN2 (0.52) | SMN1; SMN2KMT2ANPC1CASP3RAB9A | |
| SCHEMBL3849710 | 0.85 | SMN1; SMN2 (0.72) | SMN1; SMN2KMT2ANPC1CASP3RAB9A | |
| SCHEMBL3849713 | 0.85 | SMN1; SMN2 (0.72) | SMN1; SMN2KMT2ANPC1CASP3RAB9A | |
| SCHEMBL3853370 | 0.84 | SMN1; SMN2 (0.55) | SMN1; SMN2KMT2ANPC1CASP3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2889289-A1 | Pyridazine-dione N-substituted glycine derivatives as HIF hydroxylase inhibitors | GlaxoSmithKline LLC (US) | 2015-07-01 | — | — | EP | disclosed |
| US-RE44613-E1 | N-substituted glycine derivatives: hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2124565-A2 | N-SUBSTITUTED GLYCINE DERIVATIVES: HYDROXYLASE INHIBITORS | Smithkline Beecham Corporation (US) | 2009-12-02 | — | — | EP | disclosed |
| US-7608621-B2 | Such as n-{[2-[(4-bromo-2-fluorophenyl)methyl]-5-hydroxy-6-(1-methylethyl)-3-oxo-2,3-dihydro-4-pyridazinyl]carbonyl}glycine; anemia; increasing erythropoietin production | SMITHKLINE BEECHAM, CORP. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080214549-A1 | N-Substituted Glycine Derivatives: Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2008-09-04 | — | — | US | disclosed |
| WO-2008089052-A2 | N-SUBSTITUTED GLYCINE DERIVATIVES: HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214549-A1 | N-Substituted Glycine Derivatives: Hydroxylase Inhibitors | EGLN2, EGLN3, HIF1AN | SMN1; SMN2 3490/4885KMT2A 495/4885NPC1 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.